Joseph Edward Pero from 389 Manor Cir, Harleysville, PA 19438, age 48

Senior Scientific Investigator Team Leader, Scientific Fellow

view source

Location:

Harleysville, PA

Industry:

Pharmaceuticals

Work:

Glaxosmithkline Pharma Gmbh
Gsk Fellow and Scientific Team Leader
Glaxosmithkline Pharma Gmbh
Senior Scientific Investigator Team Leader, Scientific Fellow
Gsk Jan 2014 - Apr 2016
Investigator, Team Leadermedicinal Chemistry
Merck Aug 2012 - Dec 2013
Associate Principal Scientist
Merck Jul 2008 - Jul 2012
Senior Research Chemist

Education:

Harvard University 2005 - 2008
University of Rochester 2001 - 2005
Doctorates, Doctor of Philosophy, Philosophy, Chemistry University of Rochester 1999 - 2001
Master of Science, Masters, Organic Chemistry University of Rochester 1995 - 1999
Bachelors, Bachelor of Science, Chemistry

Skills:

Medicinal Chemistry
Drug Discovery
Organic Synthesis
Organic Chemistry
Drug Design
Chemistry
Synthetic Organic Chemistry
Hplc
Purification
Parallel Synthesis
Nmr
Lead Change
Organometallic Chemistry
Assay Development
High Throughput Screening
Lead Optimization
Synthetic Chemistry

Joseph Pero

view source

Joseph Pero

view source

Joseph Pero

view source

Location:

United States

Joseph Pero

view source

Location:

United States

Us Patents

Isoindoline Pde10 Inhibitors
view source
US Patent:

20130203756, Aug 8, 2013
Filed:

Oct 24, 2011
Appl. No.:

13/825616
Inventors:

Jamie L. Bunda - Douglassville PA, US
Christopher D. Cox - Lansdale PA, US
Vadim Y. Dudkin - Lansdale PA, US
Hannah D. Fiji - Boyertown PA, US
Michael J. Kelly - Wayne PA, US
Mark E. Layton - Harleysville PA, US
Joseph E. Pero - Harleysville PA, US
William D. Shipe - Chalfont PA, US
Justin T. Sheen - Perkasie PA, US
International Classification:

C07D 403/06
C07D 519/00
C07D 417/14
C07D 413/14
C07D 471/04
US Classification:

5142348, 544284, 5142662, 546173, 514314, 546122, 514300, 546121, 546177, 5483051, 514394, 548181, 514365, 544353, 514249, 544279, 5142641, 544116, 5462697, 514339, 546148, 514307, 5462754
Abstract:

The present invention is directed to isoindolinone compounds which are useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 10 (PDE10). The present invention also relates to the use of such compounds for treating neurological and psychiatric disorders, such as schizophrenia, psychosis or Huntington's disease, and those associated with striatal hypofunction or basal ganglia dysfunction.

Positive Allosteric Modulators Of Mglur2
view source
US Patent:

20130210768, Aug 15, 2013
Filed:

Jun 6, 2011
Appl. No.:

13/701039
Inventors:

Kenneth L. Arrington - Revere MA, US
Vadim Dudkin - Lansdale PA, US
Mark E. Layton - Harleysville PA, US
Joseph E. Pero - Harleysville PA, US
Alexander J. Reif - Holland PA, US
International Classification:

C07D 471/04
C07F 7/10
C07D 519/00
US Classification:

514 63, 546118, 514303, 544362, 51425304, 544349, 514249, 544 582, 5142285, 546116, 514302, 544350, 544127, 5142342, 540575, 514218, 540492, 540544, 51421115, 546114, 514301, 51421021, 546 14, 546 16, 514278
Abstract:

The present invention is directed to 5-substituted 1,3-dihydro-2H-imidazo[4,5-b]pyridine-2-one derivatives which are positive allosteric modulators of the mGluR2 receptor, useful in the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction and diseases in which the mGluR2 receptor is involved. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which metabotropic glutamate receptors are involved, such as schizophrenia.

Positive Allosteric Modulators Of Mglur2
view source
US Patent:

20130143880, Jun 6, 2013
Filed:

Aug 5, 2011
Appl. No.:

13/814870
Inventors:

Vadim Y. Dudkin - Lansdale PA, US
Mark E. Fraley - North Wales PA, US
Kenneth L. Arrington - Revere MA, US
Mark E. Layton - Harleysville PA, US
Alexander J. Reif - Holland PA, US
Kevin J. Rodzinak - Schwenksville PA, US
Joseph E. Pero - Harleysville PA, US
International Classification:

A61K 31/4745
C07D 235/26
A61K 31/4439
C07D 417/14
C07D 405/06
C07D 401/10
C07D 401/14
C07D 403/10
C07D 413/10
C07D 409/10
C07D 405/10
A61K 31/4184
C07D 413/02
C07D 401/02
C07D 403/02
A61K 31/4709
C07D 471/04
US Classification:

5142345, 5483064, 514387, 548247, 514378, 5462737, 514338, 546173, 514314, 544139, 546121, 514300, 544131, 544333, 514256, 544310, 514274, 544316, 546199, 514322
Abstract:

The present invention is directed to benzimidazolone derivatives which are positive allosteric modulators of the mGluRreceptor, useful in the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction and diseases in which the mGluRreceptor is involved. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which metabotropic glutamate receptors are involved, such as schizophrenia.

Trpv4 Antagonists
view source
US Patent:

20210299113, Sep 30, 2021
Filed:

Sep 20, 2017
Appl. No.:

16/334400
Inventors:

- Brentford, Middlesex, GB
Carl A. BROOKS - Collegeville PA, US
Brian Griffin LAWHORN - Collegeville PA, US
Peng LI - Collegeville PA, US
Jay M. MATTHEWS - Collegeville PA, US
John Jeffrey McATEE - Collegeville PA, US
Joseph E. PERO - Collegeville PA, US
Matthew Robert SENDER - Collegeville PA, US
Lamont Roscoe TERRELL - Collegeville PA, US
David J. BEHM - Collegeville PA, US
International Classification:

A61K 31/4439
A61K 45/06
C07D 401/12
C07D 207/48
A61K 31/40
C07D 417/12
A61K 31/427
C07D 403/12
A61K 31/506
C07D 498/10
A61K 31/5386
Abstract:

The present invention relates to pyrrolidine sulfonamide analogs, pharmaceutical compositions containing them and their use as TRPV4 antagonists.

Chemical Compounds
view source
US Patent:

20210253528, Aug 19, 2021
Filed:

Jul 8, 2019
Appl. No.:

16/973587
Inventors:

- Brentford, Middlesex, GB
Karen Anderson EVANS - Collegeville PA, US
Israil PENDRAK - Collegeville PA, US
Joseph E. PERO - Collegeville PA, US
International Classification:

C07D 213/64
C07C 271/28
C07C 275/30
C07C 235/20
C07D 207/273
A61K 45/06
A61K 31/506
Abstract:

The invention is directed to substituted carbon-linked bicycloalkane derivatives. Specifically, the invention is directed to compounds according to Formula (X):

Trpv4 Antagonists
view source
US Patent:

20200261411, Aug 20, 2020
Filed:

Feb 21, 2020
Appl. No.:

16/796989
Inventors:

- Brentford, GB
Carl A. BROOKS - Collegeville PA, US
Brian Griffin LAWHORN - Collegeville PA, US
Guosen YE - Collegeville PA, US
Linda S. BARTON - Collegeville PA, US
Brian W. BUDZIK - Collegeville PA, US
Jay M. MATTHEWS - Collegeville PA, US
John Jeffrey McATEE - Collegeville PA, US
Jaclyn R. PATTERSON - Collegeville PA, US
Joseph E. PERO - Collegeville PA, US
Robert SANCHEZ - Collegeville PA, US
Matthew Robert SENDER - Collegeville PA, US
Lamont Roscoe TERRELL - Collegeville PA, US
David J. BEHM - Collegeville PA, US
James V. THOMAS - Collegeville PA, US
International Classification:

A61K 31/40
C07F 7/08
C07D 513/04
C07D 491/107
C07D 417/12
C07D 409/12
A61K 45/06
A61K 31/695
A61K 31/5386
A61K 31/506
A61K 31/501
A61K 31/4439
A61K 31/429
A61K 31/427
A61K 31/4245
A61K 31/424
A61K 31/4155
A61K 31/407
A61K 31/4025
A61K 9/48
A61K 9/20
A61K 9/00
C07D 498/10
C07D 207/48
C07D 413/12
C07D 401/12
C07D 403/12
Abstract:

The present invention relates to pyrrolidine sulfonamide analogs, pharmaceutical compositions containing them and their use as TRPV4 antagonists.

N-Aryl Pyrazoles As Nrf2 Regulators
view source
US Patent:

20200071310, Mar 5, 2020
Filed:

Dec 11, 2017
Appl. No.:

16/467148
Inventors:

- Brentford, Middlesex, GB
- Cambridge, Cambridgeshire, GB
Joseph E. PERO - King of Prussia PA, US
Charlotte Mary GRIFFITHS-JONES - Cambridge, Cambridgeshire, GB
Thomas Daniel HEIGHTMAN - Cambridge, Cambridgeshire, GB
David NORTON - Cambridge, Cambridgeshire, GB
Hendrika Maria Gerarda WILLEMS - Cambridge, Cambridgeshire, GB
Alison Jo-Anne WOOLFORD - Cambridge, Cambridgeshire, GB
International Classification:

C07D 413/08
C07D 413/14
C07D 403/08
C07D 401/14
C07D 417/14
C07D 419/14
A61P 11/00
Abstract:

The present invention relates to N-aryl pyrazole compounds, methods of making them, pharmaceutical compositions containing them and their use as NRF2 regulators. In particular, the compounds of this invention include a compound of Formula (I):

Compounds
view source
US Patent:

20200055863, Feb 20, 2020
Filed:

Jul 29, 2019
Appl. No.:

16/524238
Inventors:

- Brentford, GB
Xiaomin Zhang - Shanghai, CN
Jian Wang - Shanghai, CN
Matthew Robert Sender - Collegeville PA, US
Eric Steven Manas - Collegeville PA, US
Raphael Anthony Rivero - Collegeville PA, US
Joseph E. Pero - Collegeville PA, US
Christopher Ernst Neipp - Collegeville PA, US
Vipulkumar Kantibhai Patel - Stevenage, GB
International Classification:

C07D 487/14
C07D 513/14
C07D 498/14
C07D 487/04
C07D 471/20
C07D 471/14
C07D 491/20
Abstract:

The present invention relates to novel compounds that inhibit Lp-PLAactivity, processes for their preparation, to compositions containing them and to their use in the treatment of diseases associated with the activity of Lp-PLA, for example Alzheimer's disease.